Asset Details
Do you wish to reserve the book?
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Do you wish to request the book?
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Pembrolizumab versus Ipilimumab in Advanced Melanoma
2015
Overview
In a multinational, randomized study, pembrolizumab produced significantly improved progression-free and overall survival and less high-grade toxicity than did ipilimumab in patients with metastatic melanoma.
Two therapeutic strategies have improved survival for patients with advanced melanoma in recent years: immunotherapy with checkpoint inhibitors and targeted therapies blocking BRAF and MEK.
1
BRAF and MEK inhibitors are indicated for the approximately 40 to 50% of patients with
BRAF
V600 mutations,
1
whereas immunotherapies are effective independently of
BRAF
mutational status.
2
Ipilimumab, which blocks cytotoxic T-lymphocyte–associated protein 4 (CTLA-4), a coinhibitory molecule of the immune system,
3
,
4
is approved for treating advanced melanoma on the basis of its survival benefit.
5
,
6
However, grade 3 or 4 adverse events, mostly immune-related,
7
are observed in 23% of patients.
5
,
6
When activated . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Aged
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - therapeutic use
/ Antibodies, Monoclonal, Humanized - adverse effects
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Antineoplastic Agents - adverse effects
/ Antineoplastic Agents - therapeutic use
/ Female
/ Humans
/ Immune checkpoint inhibitors
/ Male
/ Melanoma
/ Mutation
/ Patients
/ Programmed Cell Death 1 Receptor - immunology
/ Skin Neoplasms - drug therapy
/ Toxicity
/ Tumors
